Iradimed (NASDAQ:IRMD) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, October 30th. Analysts expect Iradimed to post earnings of $0.08 per share for the quarter.
Iradimed (NASDAQ:IRMD) last issued its quarterly earnings data on Tuesday, July 31st. The medical equipment provider reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $0.04. Iradimed had a net margin of 9.57% and a return on equity of 8.99%. The business had revenue of $7.38 million for the quarter, compared to analyst estimates of $7.26 million. On average, analysts expect Iradimed to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Shares of NASDAQ:IRMD opened at $26.23 on Tuesday. Iradimed has a 12 month low of $9.95 and a 12 month high of $38.78. The firm has a market cap of $277.36 million, a P/E ratio of 327.88 and a beta of 1.44.
A number of equities research analysts recently commented on the stock. ValuEngine upgraded shares of Iradimed from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 22nd. BidaskClub lowered shares of Iradimed from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 4th. Roth Capital set a $35.00 price objective on shares of Iradimed and gave the stock a “buy” rating in a report on Thursday, September 20th. Finally, TheStreet upgraded shares of Iradimed from a “c+” rating to a “b-” rating in a report on Monday, August 27th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. Iradimed currently has a consensus rating of “Buy” and an average target price of $24.67.
In related news, VP Francis X. Casey sold 55,000 shares of the firm’s stock in a transaction on Friday, September 14th. The shares were sold at an average price of $29.30, for a total value of $1,611,500.00. Following the completion of the transaction, the vice president now owns 98,779 shares of the company’s stock, valued at $2,894,224.70. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Steven M. Nardi sold 7,662 shares of the firm’s stock in a transaction on Thursday, August 2nd. The shares were sold at an average price of $23.80, for a total transaction of $182,355.60. Following the completion of the transaction, the vice president now directly owns 5,162 shares of the company’s stock, valued at approximately $122,855.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 231,556 shares of company stock valued at $6,209,841. 61.20% of the stock is owned by insiders.
A hedge fund recently raised its stake in Iradimed stock. Bank of New York Mellon Corp boosted its holdings in Iradimed Corp (NASDAQ:IRMD) by 46.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,588 shares of the medical equipment provider’s stock after purchasing an additional 7,156 shares during the period. Bank of New York Mellon Corp owned about 0.21% of Iradimed worth $469,000 as of its most recent filing with the Securities and Exchange Commission. 19.86% of the stock is owned by institutional investors.
IRadimed Corporation develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets under the MRidium name; and MRI compatible patient vital signs monitoring system under the IRadimed name.
Recommended Story: Penny Stocks, What You Need To Know
Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.